| 1 |
AJ vaccines |
Picovax IPV vaccine, Danish Medicines Agency |
Inactivated Polio Vaccine (IPV) |
IPV provides serum immunity to each poliovirus (three types) and defence against any ensuing paralysis causative disease (poliomyelitis). The mucosal immunity level in the intestine is less than that afforded by OPV, this difference may slightly show in the pharyngeal mucosal lining. Prevents poliovirus in the nervous system; immunostimulant |
Diphtheria, whooping cough, tuberculosis, tetanus, polio and bladder cancer |
2019 |
17
|
| 2 |
Grippol plus |
Quadrivalent AbbVie |
Polymer supported inactivated influenza vaccine 3-valent, egg derived adjuvanted influenza vaccine, polyoxidonium as a distinct adjuvant |
Vaccine primes advanced meticulous anti-influenza immunity formation; immunostimulant |
To treat influenza virus infection (A/H1N1 + A/H3N2) |
2018 |
18
|
| 3 |
Ys-On-001 |
Yivyka polyinosinic-polycystidylic acid/inactivated rabies virus Yisheng Biopharma |
Cancer vaccines anti-neoplastics |
B-cell stimulant, cytokines stimulant, dendritic cell stimulant, immune-modulator, macrophage modulator, natural cell stimulant, regulatory T lymphocyte inhibitor, Th1 cell stimulant |
Cancer vaccines pancreatic cancer |
2017 |
19
|
| 4 |
Adimmune’s quadrivalent flu vaccine (4142) |
Adimflu-S (QIS)BioB2B Taiwan |
Monovalent vaccine, egg-based inactivated split virus, influenza H1N1 vaccine |
Immunostimulants; inactivated virus from chick embryo culture split virus |
Influenza A (H1N1) vaccine during pregnancy |
2017 |
20
|
| 5 |
Quadrivalent influenza vaccine (J0&BB02) |
Vaxigrip Tetra QIVSanofi Pasteur |
Split influenza virus vaccine |
Induces the humeral antibodies against hemagglutinins inhibition (HAI) within 2–3 weeks; antibodies neutralize the influenza viruses |
Potent immunization against the four influenza virus strains (A and B types have two each) |
2017 |
21
|
| 6 |
NBP-608 |
SKY Zoster |
Attenuated zoster-, varicella-type vaccine |
Inducing both humoral and cellular immune response, which creates an IgG humoral immune response; varicella-zoster specifically activate CD4+ T-helper and CD8+ T-lymphocyte cells |
Varicella-zoster virus (VZV), a human neurotropic alpha-herpes-virus. Major infection causes varicella (chickenpox) |
2017 |
22
|
| 7 |
HBV-ISS (Dynavax) |
Heplisav-B |
Hepatitis B virus used for vaccine development |
Immune-stimulatory DNA sequence (ISS) ISS-1018, adjuvant proceeds TLR-9 agonist, which is used for potential prevention and treatment of HIV infection |
Treatment of HBV-, HIV viruses |
2017 |
23
|
| 8 |
GSK-1437173A |
Shingrix GSK |
Non-live, recombinant subunit vaccine; varicella vaccine herpes zoster (Hz/su) 2q4vaccine candidates |
Antigen IgE and adjuvant system AS01B develop VZV-specific immune response in a weakening immune system. Generates a long-term immune response, Shingrix helps to address age-related decline in shingles immunity |
To prevent herpes zoster (HZ) infection |
2017 |
24
|
| 9 |
DTPa-hepB-IPV-Hib |
EasySix, Hexaxim Panacea Biotech |
6 in 1 combination Infanrix hexa whole cell pertussis antigen |
The body produces its own antibodies to protect against bacteria and viruses causing different infections |
Diphtheria, DTP, Hepatitis B, Hib, IPV, Pertussis, Polio, Tetanus vaccine |
2017 |
25
|
| 10 |
Ad5-EBOVJ07BX02 |
ErveboBIB, CanSinoBIO |
Glycoprotein recombinant adenovirus type 5 Ebola virus vaccine |
Recombinant replication deficient human Ad5 vector stimulating immune responses and defending against the Ebola virus |
To treat Ebola virus |
2017 |
26
|
| 11 |
Tetravalent inactivated influenza vaccine (TIV) |
Vaxiflu-4 Zydus Cadila |
Influenza vaccine |
To increase immunity by generating antibody proteins, which defend against infection caused by the virus present in the vaccine |
Treating influenza viruses-H1N1, H3N2, Type B (Brisbane and Phuket) |
2017 |
27
|
| 12 |
Flu Vac Qs 2019–20 (4 Yr Up) CD,BL-125408 |
Flucelvax Quadrivalent Seqirus, Inc |
Cell based flu vaccines |
Vaccine motivates the body to produce its own immunity (antibodies) against the virus |
To prevent influenza A and B viruses |
2016 |
28
|
| 13 |
Quadrivalent influenza vaccine (QIV) (GQM-10) |
Vaxigrip TetraSanofi |
Inactivated influenza vaccine (split version) |
To enhance the protection from circulating influenza B viruses |
To protect against influenza (flu) viruses |
2016 |
29
|
| 14 |
Live attenuated influenza vaccine (LAIV) J07BB03 |
FluMist Quadrivalent Influenza Tetra-Medimmune |
Attenuated virus |
LAIVs induce T cell antibody-reactions against the surface protein of HA and NA; LAIVs provide hetero-subtype protection in humans |
To prevent common flu; influenza A-(H1N1), (H3N2), and B-viruses |
2016 |
30
|
| 15 |
Enterovirus type 71 vaccine (Vero cells) |
Inlive SINOVAC |
Inactivated EV 71 virus antigen vaccine |
Generate immune reactions against EV71 virus |
To prevent hand-foot-mouth disease (HFMD) caused by EV-71 |
2016 |
31
|
| 16 |
Inactivated influenza vaccine |
Cadiflu-S CBL Biologicals Pvt. Ltd |
Inactivated vaccine |
To develop immunity against the disease by forming antibodies |
To prevent influenza and protect against its effects |
2016 |
32
|
| 17 |
Inactivated quadrivalent influenza vaccine (split version) |
Afluria Quad 2020 Seqiruspty Ltd |
Influenza quadrivalent vaccine 2020 |
Against influenza-A and influenza-B type viruses |
To prevent influenza A and B viruses |
2016 |
33
|
| 18 |
Riv-4 (RIV4) |
Flublok-QSonofi Pasteur |
Quadrivalent recombinant influenza vaccine |
Humoral immune response measured by hemagglutination inhibition antibodies |
To prevent influenza A (H1N1) and B (H3N2) |
2016 |
34
|
| 19 |
Gam Evac Combi |
Combined Vector Based Vaccine |
Heterologous VSV and adenovirus type-5 vectored Ebola virus |
Heterologous prime-boost vaccine humoral immune response, cell facilitated immune response to Ebola |
To prevent Ebola viral disease (EVD) |
2015 |
35
|
| 20 |
In32 Activated Sabin polio vaccine |
Ai Bi Wei IMB China |
Inactivated Poliomyelitis (IPV) |
Inactivated vaccines offer immunity by delivering an inactivated antigen. This vaccine cannot cause disease, thus, it may be administered to an immuno-compromised host |
To prevent polio in new born babies |
2015 |
36
|
| 21 |
Rotavirus Orv-116E |
ROTAVAC 5D Vero cells Derived Bharath Biotech |
Rotavirus vaccine live attenuated monovalent vaccine |
Rotarix (vaccine prevents rotavirus infectivity) reproduces in the small intestine and induces immunity; the particular mechanistic action of immunology by rotarix against rotavirus gastroenteritis is unknown |
To prevent rotavirus gastroenteritis |
2015 |
37
|
| 22 |
NBP-607-QIV |
SKY cell flu Quadrivalent SK Bioscience |
Cell cultured quadrivalent inactivated subunit influenza vaccine |
Immunity for influenza viruses A and B subtypes. Sero-protection is generally obtained within three weeks |
To treat influenza virus infections |
2015 |
38
|
| 23 |
GC-3110A, GC-3110B |
GCflu Quad GC Pharma |
Quadrivalent influenza virus vaccine |
Hemagglutination inhibition antibody response |
To treat influenza virus infections |
2015 |
39
|
| 24 |
Chimerivax-dengue (CYD-TDV) |
Dengvaxia Sanofi Pasteur |
Live attenuated tetravalent chimeric vaccine |
Antibody dependent improvement |
To prevent Dengue virus-1, 2, 3 and 4 fever in humans |
2015 |
40
|
| 25 |
H5N1 influenza (avian flu) vaccine (Rx) |
Audenz Vn-101 Sonali Pasteur GSK |
Egg based H5N1 vaccines, inactivated influenza virus vaccine |
Induces immunity (antibodies), which act against viral HA in the vaccine, after interrupting viral attachment to human respiratory cells, provides immunity to influenza A virus subtype H5N1 |
To treat influenza virus |
2014 |
41
|
| 26 |
9-Valent HPV vaccine [9v HPV] |
GARDASIL 9 |
Recombinant virus |
Prevent HPV through humoral immune responses induced by the vaccine |
Prevention of cervical, vuvar, vaginal, anal, or pharyngeal, head and neck cancer; by preventing papilloma virus (HPV) infection |
2014 |
42
|
| 27 |
Cell cultured-H5N1 vaccine KD-295 |
GSK |
Emulsion cell culture influenza HA vaccine (Prototype) |
Antibody titer calculated through hemagglutination inhibition (HI): high-titer virus generation led to suspension of growth of MDCK (Madin–Darby Canine Kidney) and Vero cells in a serum-free distribution |
To prevent influenza A virus H5N1 |
2014 |
43
|
| 28 |
Live modified vaccine virus Ankara Ankara-Bavarian Nordic (MVA-BN)-J07BX |
IMVANEX/IMVAMUNE JYNNEOS |
Non-replicating small pox vaccine |
Non-replicating and capable of generating humoral and cellular immune response to orthopox-viruses |
To prevent smallpox |
2013 |
44
|
| 29 |
Japanese encephalitis vaccine BBIL/JEV |
JENVAC Bharath Biotech |
Inactivated Vero cell-derived viral vaccine |
JENVAC is sufficient to elicit an immune response |
To protect against Japanese encephalitis virus (JEV) |
2013 |
45
|
| 30 |
Fluzone quadrivalent BL 103914/J07B B |
FLUZONE Quadrivalent Sanofi Pasteur Inc. |
Inactivated quadrivalent influenza virus vaccine type A and type B (split version) |
Stimulates the production of specific antibodies |
Prevents influenza diseases, type A and B |
2013 |
46
|
| 31 |
FLU-Q-QIV flu laval quadrivalent GSK-2282511A |
FluLaval™ Quadrivalent Glaxo Smith Kline (GSK) |
Influenza virus vaccine |
Vaccines which improve immunity against the viral pathogen leading to influenza: they induce the generation of antibodies |
Prevents influenza diseases, type A and B |
2013 |
47
|
| 32 |
DTa-IPV-HePB-HibHexavalent vaccine6-in-1 vaccine J07CA09 |
Hexyon, Infanrix, Vaxelis |
Hexavalent vaccine |
Booster vaccination |
To treat DTaP, hepatitis B, polio, haemophilus influenza diseases |
2013 |
48
|
| 33 |
GSK-2282512a BL 125127 |
Fluarix Quadrivalent (FLU Q-QIV) Glaxo Smith Kline Biologicals |
Inactivated influenza vaccine, quadrivalent, seasonal |
Increases immunity for treatment of disease originating from influenza-A subtype and type B viruses |
Prevents disease triggered by influenza A subtype and type B viruses |
2012 |
49
|
| 34 |
ChimeriVax™-JE |
IMOJEV Sanofi |
Live attenuated Japanese encephalitis vaccine (JEV), monovalent |
IMOJEV is highly immunogenic and able to induce continuing immunity through both preclinical and clinical trials |
To prevent yellow fever virus |
2012 |
50
|
| 35 |
Prepandemic influenza vaccine (H5N1) J07BB01 |
Vepacel |
Inactivated flu strain known as A/Vietnam/1203/2004 (H5N1) whole virion, derived from inactivated Vero cells |
Overall the vaccine primes the immune system |
Protect against influenza H5N1 (bird flu) |
2012 |
51
|
| 36 |
Medi-3250STN: 125020 |
FLUMIST Quadrivalent Med-Immune |
Influenza vaccine, live attenuated influenza vaccine (LAIV) |
To provide immunity against influenza virus caused by subtypes A and B |
Protects against influenza |
2012 |
52
|
| 37 |
Hepatitis E hecolin (HEV-239) |
Hecolin Xiamen Innovax Biotech |
Non enveloped virus with positive sense HEV vaccine, a recombinant vaccine |
HEV 239 treatment induces a strong anti-HEG IgG response, through early antibody mobilisation |
Fights against hepatitis-E virus |
2012 |
53
|
| 38 |
Measles/rubella vaccine |
German measles |
Live attenuated (weakened) viruses |
Immunostimulant, produces antibodies (associated proteins fight and kill measles, mumps, and rubella (MMR) viruses |
Prevent MMR viruses |
2011 |
54
|
| 39 |
Human inactivated influenza vaccine (H1N1) 2009 vaccine. Pandemic influenza strain A/California/7/2009/nyMC X-179A |
HNVAC (Bharath Biotech) |
Inactivated Influenza A virus vaccine (H1N1). Cell culture derived vaccine |
Active immunization agent, which acts against the influenza A (H1N1) 2009 virus |
Activity against influenza A |
2010 |
55
|
| 40 |
Influenza A virus (H1N1), monovalent vaccine |
2009 Influenza A (H1N1), Sonali Pasteur |
Monovalent vaccine, adjuvant |
Active immunization for preventing disease caused by influenza virus A (H5N1) |
To prevent influenza A viral disease |
2010 |
56
|
| 41 |
Quadrivalent flu vaccine |
FLUCELVAX |
Cellular influenza vaccine |
Active immunization for preventing influenza subtypes A and B causative diseases |
To defend against four different strains of influenza for both subtypes A and B |
2010 |
57
|
| 42 |
Influenza vaccine (whole virion). Inactivated combination |
Vaxiflu-S Fluzone Zydus Cadila Healthcare Ltd |
Inactivated influenza vaccine (NZ) |
Active immunization for preventing Vaxiflu-X |
To assist in protection against influenza |
2010 |
58
|
| 43 |
H1N1 pandemic influenza vaccine H5N1 strain of the flu virus A/Vietnam/1203/2004Flu strain/California/07/2009 (H1N1) virus |
Celvapan Baxter International |
Whole virion in Vero cell-based influenza vaccine, inactivated |
Motivates the immune system to produce antibodies when exposed to the virus |
To protect against the influenza strains of H5N1 virus |
2009 |
59
|
| 44 |
Influenza A virus vaccine H5N1 |
Fluval P-H5N1 Omninvest |
Fluart innovative vaccine |
Fluval affords active immunization against four virus strains; two for influenza A subtype, and two for B type |
To prevent influenza a (H5N1) |
2009 |
60
|
| 45 |
Non adjuvant influenza A (H1N1) 2009 monovalent vaccine. Influenza hemagglutinin (HA) A/California/07/2009 (H1N1) V-like virus |
Panenza Sanofi-Pasteur |
Non-adjuvanted pandemic vaccine |
Induces a high immune (antibody) response, three weeks post-vaccination |
To prevent influenza A (H5N1) |
2009 |
61
|
| 46 |
Monovalent, cell culture-derived, inactivated subunit influenza vaccine. Produced from A/California/07/2009 (H1N1) with adjuvant MF-59 |
Celtura |
MF-59 adjuvanted cell cultured derivative A/H1N1 pandemic influenza vaccine |
MF-59 induces a strong response in adults and substantially develops the response with growth of HA-specific Tfh (CD4+, ICOS+, CXCR5+, IL-21+) cells |
Induces an immune response for protection against influenza virus |
2009 |
62
|
| 47 |
Pandemic (H1N1) ASO3 adjuvanted influenza vaccine |
Pandremix GSK |
Combination of H1N1 virus antigen and adjuvant system of H1N1 |
Enhances the natural immunity of the body |
To prevent influenza A (H1N1), swine flu viral infections |
2009 |
63
|
| 48 |
Influenza vaccine (H1N1) flu strain from A/California/7/2009 (H1N1) derived strain NYMC-181 J07BB02 |
Focetria |
Surface antigen (hemagglutinin and neuraminidase) inactivated adjuvant |
Vaccine acts by priming the immune system |
To protect against influenza type A (H1N1) 2009 virus |
2009 |
64
|
| 49 |
Cell culture-derived adjuvanted influenza virus vaccine (Grippol TC |
Grippol NeoSolvay pharmaceutical AbbVie |
Cell based adjuvanted influenza vaccine |
Activates the endosomal receptor, which leads non-specific activation of the surface TLRs, which induce the intracellular signals contributing to the antiviral mechanism |
To prevent influenza virus infections |
2009 |
65
|
| 50 |
Inactivated H5N1 influenza (avian flu) vaccine A/Vietnam/1194/2003/(H5N1) RG |
Pan-flu (Sinovac Biotech) |
Single shot vaccine against H1N1 influenza |
Body reacts by creating antibodies |
To prevent H5N1 pandemic influenza |
2008 |
66
|
| 51 |
Pandemic influenza vaccine |
Panvax H1N1 vaccine |
Split virion inactivated vaccine |
Panvax, is an inactive viral part of H1N1, the immune system responds by developing antibodies to the virus particle |
Influenza virus (H1N1), swine flu infections |
2008 |
67
|
| 52 |
Pre-pandemic influenza vaccine H5N1 (split virion, adjuvanted, inactivated) AS03-H5N1 vaccine A/Vietnam/1194/2004; or A/Indonesia/5/2005 GSK-1562902a |
Prepandrix GSK |
Split virion, inactivated, adjuvanted; hemagglutinin, antigen, adjuvanted |
Potential immunization against influenza A subtype H5N1 virus |
Influenza (H5N1) virus, swine flu infection |
2008 |
68
|
| 53 |
Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) J07BB02 |
Optaflu Flucelvax TETRA Novartis |
Influenza virus surface antigens, hemagglutinin and neuraminidase subunit vaccines |
Optaflu comprising different strain surface regions of the flu virus. Vaccine causes immune system to recognize the unknown viral components and produce antibodies against them |
Prevent influenza viral infection |
2008 |
69
|
| 54 |
Smallpox (vaccinia) vaccine ACAM2000 |
Acam-2000 Sanofi Pasteur Biologics Co. |
The vaccine is made from a live virus, vaccinia |
Possessing potent immunization against smallpox |
Prevention of smallpox |
2007 |
70
|
| 55 |
Inactivated quadrivalent influenza vaccine (split virion) |
Afluria Seqirus Pty. Ltd. |
Quadrivalent split virion, influenza virus hemagglutinin as the active ingredient. |
Immunity against 3 (type A (2) and type B (1)) or 4 (type A (2) and type B (2)) microbial strains. Suitable for the annual flu season |
To stop infection caused by influenza virus |
2007 |
71
|
| 56 |
H5N1 avian flu vaccine, avian influenza or bird flu, vaccine is derived from A/Vietnam/1203/2004 influenza virus |
Fluzone Sanofi Pasteur |
Inactivated influenza virus vaccine |
Provides protection against the H5N1 influenza virus stimulating the immune response |
To prevent infection caused by influenza virus |
2007 |
72
|
| 57 |
Adjuvanted H5N1 pre-pandemic vaccine |
Daronix, GSK |
Second generation pandemic vaccine |
Prepare the body’s immune system to prevent a flu epidemic |
Prevent common flu disease |
2007 |
73
|
| 58 |
Influenza vaccine surface antigen, inactivated, prepared in cell culture: A/California/7/2009 (H1N1) pdm09-like strain, A/Switzerland/9715293/2013 (H3N2)-like strain, B/Phuket/3073/2013-like strain |
Optaflu |
Vaccine containing flu surface antigen |
Enhances the body’s defence system, priming the immune system to make antibodies against the flu virus |
To prevent infection caused by influenza virus |
2007 |
74
|
| 59 |
Birch pollen allergy vaccine |
Oralgen Birch Pollen ALK-Abello |
Peptide based vaccine |
Suppression of allergic reactions after immunization with fusion protein, which is caused by releasing the immune messenger interleukin-10 (IL-10), an autologous cytokine, functioning to decrease the overacting immune response |
To prevent allergy |
2007 |
75
|
| 60 |
Influenza vaccine, split virion, inactivated hemagglutinin of A/California/7/2009 Hemagglutinin of A/Victoria/210/2009 Hemagglutinin of B/Brisbane/60/2008 |
Anflu Sinovac |
Split virion, inactivated |
Body generates immuno-reactions against influenza virus |
To prevent infection caused by influenza virus |
2006 |
76
|
| 61 |
Rec hepatitis B vaccine |
Supervax |
Hepatitis B vaccine, immunoglobulin (HBIG) |
Active immunization of hepatitis B vaccine induces the immune system to create anti-HBs without an active infection risk |
To prevent infection against hepatitis B virus |
2006 |
77
|
| 62 |
Antirabies vaccine |
RABIRIX Bharath Biotech |
Vero cell based rabies vaccine (PVRV) |
Inactivated virus vaccine boosts immunization against rabies |
To prevent infection against rabies virus |
2006 |
78
|
| 63 |
Live herpes zoster vaccine |
Zostavax Merck |
Live attenuated virus vaccine |
Enhancing VZV – specific immunity against zoster |
Treatment for herpes zoster/postherpetic neuralgia (PHN), a neuropathic pain |
2006 |
79
|
| 64 |
Rotavirus vaccine, live rotavirus 116E strain derived in Vero cells |
RotaTeq Bharath Biotech |
Live attenuated, oral, monovalent |
Active immunization for infants from the age of 6 weeks |
To protect against rotavirus gastro-enteritis disease in infants and young children |
2006 |
80
|
| 65 |
Human papillomavirus quadrivalent (type 6, 11, 16, and 18) vaccine (HPV vaccine) J07BM01 |
Gardasil, Cervarix Merck |
Protein subunit quadrivalent, recombinant |
Body’s immune system identifies the viral proteins in Gardasil, develops antibodies against them |
To protect against either two or four or nine types of HPV (cervical, vaginal and vulvar in females) |
2006 |
81
|
| 66 |
Rotavirus vaccine with five strains of rotavirus, from both human and animal sources |
ROTARIX |
Live, attenuated, oral |
Usually to develop immunity against rotavirus-based disease |
Rotarix vaccine assists to prevent this disease in children |
2005 |
82
|
| 67 |
Hepatitis B (r DNZ) vaccine, adjuvanted, absorbed J07BC01 |
Fendrix GSK |
Adjuvanted, absorbed, recombinant DNA technology |
Vaccine works by priming the immune system |
Prevents hepatitis B virus infection |
2005 |
83
|
| 68 |
MR vaccine freeze-dried, live, attenuated, measles-rubella combined vaccine |
Mearubik, Mitsubishi Tanabe Pharma Corporation |
Live vaccine for measles, rubella |
Immune system induced to produce antibodies (proteins that fight and also kills the rubella virus) |
To prevent rubella virus |
2005 |
11
|
| 69 |
Inactivated hepatitis A and hepatitis B (rDNA) – HAB adsorbed vaccine |
Bilive Sinovac |
Recombinant DNA technology |
Suboptimal immune response to the vaccine |
Prevents hepatitis B viral infection |
2005 |
84
|
| 70 |
Virosomal influenza vaccine, Invivac influenza vaccine |
Invivac Solvay Pharmaceuticals |
Adjuvant |
The virosome mechanism remains complex; it is the transporter as well as an immune stimulant |
To treat influenza |
2004 |
85
|
| 71 |
Influenza virus (live) (LAIV), inactivated influenza vaccine (IIV) |
Flumist |
Wild-type |
Disease-causing viruses has been attenuated and inactivated, using the influence of heat/chemicals such as formaldehyde |
Protects against infection from influenza viruses |
2003 |
86
|
| 72 |
Hepatitis A and B Vac DB10989, DB11627 |
Ambirix |
Vaccine based |
B-lymphocytes anti-HBs antibodies |
Immunization against hepatitis A and B viral infectivity |
2003 |
87
|
